<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/901064D6-410C-4BE9-BAE4-2FDABA88CCAC"><gtr:id>901064D6-410C-4BE9-BAE4-2FDABA88CCAC</gtr:id><gtr:firstName>Marc</gtr:firstName><gtr:otherNames>Willem</gtr:otherNames><gtr:surname>van der Kamp</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2A2990B1-E1E1-4888-8848-7C256C3A3B43"><gtr:id>2A2990B1-E1E1-4888-8848-7C256C3A3B43</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Mulholland</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FM015378%2F1"><gtr:id>34BBB6C8-309A-4C9F-8F24-91A2CB3E64F2</gtr:id><gtr:title>Predicting drug-target binding kinetics through multiscale simulations</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/M015378/1</gtr:grantReference><gtr:abstractText>Drug-target binding kinetics has recently emerged as a critical parameter in determining the in vivo efficacy and toxicity of lead compounds. Unfortunately, the rational optimisation of this parameter to design more effective and less toxic drugs is extremely difficult as the features of small ligands and their protein targets that affect binding kinetics remain poorly understood. 
The aim of this project is to systematically fill this knowledge gap by combining state of the art computational approaches. We propose to combine our state-of-the-art enhanced sampling and QM/MM methods to compute reliable association free energy profiles and rationalise the binding kinetics of receptor-ligand complexes in terms of the structures and energies of the transition state ensemble. 
We will test and validate these methods, which have not been previously combined for this purpose. Together, they tackle the two central challenges of biomolecular simulation, i.e. conformational sampling and accuracy of potentials. We will apply the techniques we develop to well-characterised biomolecular systems of real biomedical importance, such as the influenza target neuraminidase, the anti-cancer targets p38a, Abl, Src and FGFr tyrosine-kinases, the chaperone HSP90, and other drug targets in collaboration with our pharmaceutical industrial partners (UCB, GSK and Sanofi). The results will shed new light on the kinetics of drug binding and their molecular origins. The methods we develop should find wide application, and we will make them available and accessible.</gtr:abstractText><gtr:fund><gtr:end>2019-04-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2015-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>225396</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Industrial collaboration with EVOTEC</gtr:description><gtr:id>46A742FE-604E-4A9D-B8F3-F7AF52C77A3D</gtr:id><gtr:impact>The collaboration is multi-disciplinary involving Computational Chemistry, Chemical Biology, Structural Biology, Cellular Biology and Drug Discovery.
A new manuscript is in preparation and will soon be submitted to a very prominent and high-impact journal. 
The PI (FLG) has been invited to a number of high-profile national international (ACS-meeting) conferences to discuss the results.</gtr:impact><gtr:partnerContribution>Evotec provided a plethora of unpublished experimental data on the binding mode and on the biological effect of the new tool compound in cells.</gtr:partnerContribution><gtr:piContribution>We helped EVOTEC to rationalize the binding mode of a novel allosteric modulator of FGFR. By using our novel &amp;quot;SWISH&amp;quot; Hamiltonian Replica exchange algorithm, we predicted a previously unknown binding cavity in the D3 domain of FGFR3c, which was then validated by NMR spectroscopy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Collaboration with Bristol university on predicting drug-target binding kinetics</gtr:description><gtr:id>66D71739-6053-4840-9213-6E00277027FE</gtr:id><gtr:impact>A combined computational platform to predict binding kinetics and model the transition state ensemble.</gtr:impact><gtr:partnerContribution>Prof. Mulholland's contributed his QMMM algorithms as well as Waterswap to the combined computational platform.</gtr:partnerContribution><gtr:piContribution>We contributed our enhanced sampling simulation algorithms including TS-PPTIS. Our approach will be combined with Prof. Mulholland's QM/MM algorithms to accurately predict binding kinetics.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial PhD studentship</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Heptares Therapeutics Ltd</gtr:fundingOrg><gtr:id>C9F1BFAD-369D-45C3-9321-E2A9146273B8</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Drug-target binding kinetics has recently emerged as a critical parameter in determining the in vivo efficacy and toxicity of lead compounds. Unfortunately, the rational optimisation of this parameter to design more effective and less toxic drugs is extremely difficult as the features of small ligands and their protein targets that affect binding kinetics remain poorly understood. 

The aim of this project is to systematically fill this knowledge gap by combining state of the art computational approaches. We propose to combine our state-of-the-art enhanced sampling and QM/MM methods to compute reliable association free energy profiles and rationalise the binding kinetics of receptor-ligand complexes in terms of the structures and energies of the transition state ensemble. 

We will test and validate these methods, which have not been previously combined for this purpose. Together, they tackle the two central challenges of biomolecular simulation, i.e. conformational sampling and accuracy of potentials. We will apply the techniques we develop to well-characterised biomolecular systems of real biomedical importance, such as the influenza target neuraminidase, the anti-cancer targets p38a, Abl, Src and FGFr tyrosine-kinases, the chaperone HSP90, and other drug targets in collaboration with our pharmaceutical industrial partners (UCB, GSK and Sanofi). The results will shed new light on the kinetics of drug binding and their molecular origins. The methods we develop should find wide application, and we will make them available and accessible.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>16AA6B9A-E0FB-4AD3-9569-222A28A271DB</gtr:id><gtr:impactTypes/><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We developed a novel and effective computational approach to predict cryptic binding sites on targets of pharmaceutical interest.</gtr:description><gtr:id>483802CB-A73B-4082-8754-7CB2D0D09F7C</gtr:id><gtr:impact>The method has been described in an high-impact publication (JACS) and in a number of high-profile blogs in drug discovery. The PI has been invited by Pfizer and other pharmaceutical companies to give talks about the method.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SWISH a new Hamiltonian Replica Exchange-based computational algorithm</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>We developed a new interoperable plug-in compatible with PLUMED and many widely-used MD codes (such as GROMACS) to run our TS-PPTIS approach for binding kinetics. The tool can be used to predict ligand and folding binding kinetics.</gtr:description><gtr:id>5B5ED8B6-6464-476E-BF31-772D929B7C55</gtr:id><gtr:impact>The tool is able to accurately predict the binding kinetics of drugs to their biological targets, paving the avenue to the rational design of new molecules with fine-tuned biomedical effects.</gtr:impact><gtr:openSourceLicense>true</gtr:openSourceLicense><gtr:title>Plug-in and scripts for enhanced-sampling molecular simulations.</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8659FDC7-7714-4CC5-A6BC-9537727E0E6A"><gtr:id>8659FDC7-7714-4CC5-A6BC-9537727E0E6A</gtr:id><gtr:title>The Catalytic Mechanism of a Natural Diels-Alderase Revealed in Molecular Detail.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fe9ce646314a800e48225d08d9d5a42b"><gtr:id>fe9ce646314a800e48225d08d9d5a42b</gtr:id><gtr:otherNames>Byrne MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23D2B396-20D9-46B4-93D0-D3E5B72C6E4E"><gtr:id>23D2B396-20D9-46B4-93D0-D3E5B72C6E4E</gtr:id><gtr:title>Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e234490041d708c6a7afabb04e182b9a"><gtr:id>e234490041d708c6a7afabb04e182b9a</gtr:id><gtr:otherNames>Lovera S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/60F48F1D-5D04-466D-8777-623F92151E8E"><gtr:id>60F48F1D-5D04-466D-8777-623F92151E8E</gtr:id><gtr:title>Conformational transition of FGFR kinase activation revealed by site-specific unnatural amino acid reporter and single molecule FRET.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42d5082e04b2ac8642ea81de1727332d"><gtr:id>42d5082e04b2ac8642ea81de1727332d</gtr:id><gtr:otherNames>Perdios L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6187D3EB-AD45-4D97-9BEE-E86AB225A129"><gtr:id>6187D3EB-AD45-4D97-9BEE-E86AB225A129</gtr:id><gtr:title>Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms.</gtr:title><gtr:parentPublicationTitle>Accounts of chemical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e80bc5a77964ae98459a6162e973d0c9"><gtr:id>e80bc5a77964ae98459a6162e973d0c9</gtr:id><gtr:otherNames>Cavalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-4842</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDE3C4DB-7CCF-4B69-9E21-68CCDEE45D93"><gtr:id>CDE3C4DB-7CCF-4B69-9E21-68CCDEE45D93</gtr:id><gtr:title>Rapid Estimation of Catalytic Efficiency by Cumulative Atomic Multipole Moments: Application to Ketosteroid Isomerase Mutants.</gtr:title><gtr:parentPublicationTitle>Journal of chemical theory and computation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/75d3af4967d6051eadb0b7687b2978ed"><gtr:id>75d3af4967d6051eadb0b7687b2978ed</gtr:id><gtr:otherNames>Beker W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-9618</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/214F5301-550E-4C5A-9E15-B93B1408423B"><gtr:id>214F5301-550E-4C5A-9E15-B93B1408423B</gtr:id><gtr:title>Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36dc955f7ab14eccfd00a3d48d85a8e6"><gtr:id>36dc955f7ab14eccfd00a3d48d85a8e6</gtr:id><gtr:otherNames>Morando MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AD9FB99-8A75-4AC9-A68C-7DE1353517A7"><gtr:id>8AD9FB99-8A75-4AC9-A68C-7DE1353517A7</gtr:id><gtr:title>Insights into the Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures of the Catalytic Domain of MCR-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/befc58d95b309466ced570b65ae0e450"><gtr:id>befc58d95b309466ced570b65ae0e450</gtr:id><gtr:otherNames>Hinchliffe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B556560-0B2F-4719-B859-29A6CDCB6830"><gtr:id>5B556560-0B2F-4719-B859-29A6CDCB6830</gtr:id><gtr:title>DNA-binding protects p53 from interactions with cofactors involved in transcription-independent functions.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/df48f1f607f1ab996d26152cf9344fce"><gtr:id>df48f1f607f1ab996d26152cf9344fce</gtr:id><gtr:otherNames>Lambrughi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71FE5494-9C12-4528-A38F-3CD6C2D4648B"><gtr:id>71FE5494-9C12-4528-A38F-3CD6C2D4648B</gtr:id><gtr:title>Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8688b7713b80c26fa3e3fd9f54663fc7"><gtr:id>8688b7713b80c26fa3e3fd9f54663fc7</gtr:id><gtr:otherNames>Oleinikovas V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/M015378/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>